Mucosal safety of PHI-443 and stampidine as a combination microbicide to prevent genital transmission of HIV-1

Fertil Steril. 2007 Oct;88(4 Suppl):1197-206. doi: 10.1016/j.fertnstert.2007.01.131. Epub 2007 May 11.

Abstract

Objective: To investigate the in vitro and in vivo mucosal safety of a nonnucleoside reverse transcriptase (RT) inhibitor (PHI-443) and a nucleoside analogue RT inhibitor (stampidine)-based anti-HIV microbicide either alone or in combination.

Design: In vitro and in vivo studies using three-dimensional vaginal epithelia integrating Langerhans cells and 16 New Zealand White rabbits, respectively.

Setting: Research laboratory.

Intervention(s): Rabbits in groups of four were exposed intravaginally to a gel with and without 1% PHI-443, 1% stampidine, or 1% PHI-443 plus 1% stampidine for 14 days. Cytokine/chemokine release by three-dimensional co-cultures in the presence and absence of PHI-443 or stampidine.

Main outcome measures(s): Histologic scoring of vaginal tissue for mucosal toxicity at 24 hours after dosing. Simultaneous evaluation of levels of 10 cytokines (granulocyte-macrophage colony-stimulating factor, interleukin-1 alpha, interleukin-13, macrophage inflammatory protein-1 beta, granulocyte colony-stimulating factor, interleukin-18, tumor necrosis factor-alpha, interleukin-6, interleukin-1 beta, and interferon-gamma) and 6 chemokines (epithelial neutrophil-activating peptide-78, interleukin-8, monocyte/macrophage chemoattractant protein-1, macrophage inflammatory protein-3 alpha, interferon-inducible protein-10, and regulated upon activation of normal T-cell expressed and secreted) in culture media by a multiplexed chemiluminescence-based immunoassay.

Result(s): In the rabbit model, repeated intravaginal administration of PHI-443 plus stampidine via a gel formulation at concentrations nearly 2,000 and 10,000 times higher than their respective in vitro anti-HIV IC(50) values did not result in vaginal irritation. The levels of proinflammatory cytokines/chemokines secreted by multilayered human genital epithelia integrating Langerhans cells were unaffected by prolonged exposure to PHI-443 or stampidine.

Conclusion(s): The combination of PHI-443 and stampidine was noncytotoxic to vaginal epithelial cells, nonirritating to vaginal mucosa, and did not induce the secretion of proinflammatory cytokines and chemokines by co-cultures of human genital epithelia and Langerhans cells. These attributes are particularly useful for the clinical development of PHI-443 and stampidine as a combination microbicide and as a prophylactic anti-HIV agent to curb genital transmission of HIV-1 by semen.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Intravaginal
  • Animals
  • Anti-Infective Agents, Local / administration & dosage
  • Anti-Infective Agents, Local / adverse effects*
  • Dideoxynucleotides
  • Drug Therapy, Combination
  • Female
  • HIV Infections / prevention & control
  • HIV Infections / transmission*
  • HIV-1 / drug effects*
  • Humans
  • Mucous Membrane / cytology
  • Mucous Membrane / drug effects
  • Mucous Membrane / physiology
  • Pyridines / administration & dosage
  • Pyridines / adverse effects*
  • Rabbits
  • Stavudine / administration & dosage
  • Stavudine / adverse effects
  • Stavudine / analogs & derivatives*
  • Thiourea / administration & dosage
  • Thiourea / adverse effects
  • Thiourea / analogs & derivatives*
  • Thymidine Monophosphate / administration & dosage
  • Thymidine Monophosphate / adverse effects
  • Thymidine Monophosphate / analogs & derivatives*
  • Vagina / cytology
  • Vagina / drug effects*
  • Vagina / physiology

Substances

  • Anti-Infective Agents, Local
  • Dideoxynucleotides
  • HI 443
  • Pyridines
  • stampidine
  • Thymidine Monophosphate
  • Stavudine
  • Thiourea